Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients
The DOI matches its Crossref record.
Abstract
OBJECTIVE: New evidence indicates that treatment response can be predicted with high sensitivity after 2 weeks of treatment. Here, we assess whether early improvement with antidepressant treatment predicts treatment outcome in patients with major depressive disorder (MDD). DATA SOURCES: Forty-one clinical trials comparing mirtazapine with active comparators or placebo in inpatients and outpatients (all-treated population, N = 6907; intent-to-treat population, N = 6562) with MDD (DSM-III-R or DSM-IV Criteria) were examined for early improvement (>or= 20% score reduction from baseline on the 17-item Hamilton Rating Scale for Depression [HAM-D-17] within 2 weeks of treatment) and its relationship to treatment outcome. STUDY SELECTION: Data were obtained from a systematic search of single- or double-blind clinical trials (clinical trials database, Organon, a part of Schering-Plough Corporation, Oss, The Netherlands). All included trials (a total of 41) employed antidepressant treatment for more than 4 weeks and a maximum of 8 weeks. The studies ranged from March 1982 to December 2003. Trials were excluded if there were no HAM-D-17 ratings available, no diagnosis of MDD, or if the study was not blinded. Trials were also excluded if HAM-D-17 assessments were not available at week 2, week 4, and at least once beyond week 4. DATA SYNTHESIS: Early improvement predicted stable response and stable remission with high sensitivity (>or= 81% and >or= 87%, respectively). Studies utilizing rapid titration vs. slow titration of mirtazapine demonstrated improved sensitivity for stable responders (98%, [95% CI = 93% to 100%] vs. 91% [95% CI = 89% to 93%]) and stable remitters (100%, [95% CI = 92% to 100%] vs. 93% [95% CI = 91% to 95%]). Negative predictive values for stable responders and stable remitters were much higher (range = 82%-100%) than positive predictive values (range = 19%-60%). CONCLUSIONS: These results indicate that early improvement with antidepressant medication can predict subsequent treatment outcome with high sensitivity in patients with major depressive disorder. The high negative predictive values indicate little chance of stable response or stable remission in the absence of improvement within 2 weeks. A lack of improvement during the first 2 weeks of therapy may indicate that changes in depression management should be considered earlier than conventionally thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although 60% of persons who achieved remission in the STAR * D trial with level 1 treatment did so after week 6 of treatment”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [168]
In the citing paper
“The adequate duration of an antidepres sant trial is generally considered to be 4- 6 weeks at optimal dosing”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [168]
In the citing paper
“the partial responses at 2 weeks have, nonetheless, been shown to be strongly correlated with subsequent remission [19,51].”
Citations
Cited by
Items 201–300 of 341
Antidepressants: Indications, Contraindications, Interactions, and Side Effects
Corponi, F., Fabbri, C., & Serretti, A. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_29-1 · Cited by 15
McIntyre, R. S., Gommoll, C., Chen, C., & Ruth, A. (2016) · CNS Spectrums · doi:10.1017/s1092852915000899 · Cited by 11
“The broader importance of early symptom improvement has been established in a meta-analysis of 41 MDD clinical trials that included different classes of antidepressant medications.(22) Results of this analysis showed that a ≥20% decrease in overall depression severity at Week 2 was highly predictive of “stable” respon…”
BackgroundWang, T., Li, L., Yue, Y., Liu, X., Chen, S., Shen, T., Xu, Z., & Yuan, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.042 · Cited by 10
Whose depression deteriorates during acute phase antidepressant treatment?
Akechi, T., Sugishita, K., Chino, B., Itoh, K., Ikeda, Y., Shimodera, S., Yonemoto, N., Miki, K., Ogawa, Y., Takeshima, N., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.052 · Cited by 12
Park, C. I., Kim, H. W., Jeon, S., Hwang, E. H., Kang, J. I., & Kim, S. J. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05630-9 · Cited by 12
“…Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul 03722, Republic of Korea Early prediction of response or nonresponse to pharmacological treatment could shorten the exposure to ineffectivemedications and optimize the sequential therapeutic approaches (Szegedi et al. 2009).”
BackgroundSumiyoshi, T., Hoshino, T., Mishiro, I., Hammer-Helmich, L., Ge, H., Moriguchi, Y., Fujikawa, K., & Fernandez, J. L. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.09.025 · Cited by 10
Hsu, J.-W., Su, T., Huang, C.-Y., Chen, Y.-S., & Chou, Y.-H. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c091a · Cited by 11
“Interestingly, 2 recent large-scale meta-analyses studies have concluded that treatment with SSRIs is associated with symptomatic improvement in depression by the end of the first week of use and early improvement with antidepressant medication can predict subsequent treatment outcome.(28,29) In the present study, we…”
BackgroundLaux, G., Huttner, N. A., & the VIVALDI study group (2014) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2014.892138 · Cited by 9
Novel Augmentation Strategies in Major Depression.
Martiny, K. (2017) · PubMed · Cited by 12
Yuan, H., Zhu, X. L., Luo, Q., Halim, A., Halim, M., Yao, H., Cai, Y., & Shi, S. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s196533 · Cited by 11
Huntley, E. D., Swanson, L. M., Kolenic, G. E., Bertram, H. S., Mooney, A., Dopp, R. R., & Arnedt, J. T. (2019) · Behavioral Sleep Medicine · doi:10.1080/15402002.2019.1695617 · Cited by 9
“This early improvement is positively correlated with long-term treatment outcomes (Henkel et al., 2009; Stassen, Angst, Hell, Scharfetter, & Szegedi, 2007; Szegedi et al., 2009; Tadic et al., 2010).”
BackgroundKandilarova, S., Terziyski, K. V., Draganova, A. I., Stoyanov, D., Akabaliev, V., & Kostianev, S. S. (2017) · Folia Medica · doi:10.1515/folmed-2017-0040 · Cited by 9
Wang, C., Lan, X., Liu, W., Zhan, Y., Zheng, W., Chen, X., Liu, G., Mai, S., Lu, H., McIntyre, R. S., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03027-2 · Cited by 10
“Symptom improvement was de fi ned as a decrease ≥ 20% from baseline in MADRS score, according to Lipsitz et al. [23], based on the criteria commonly applied in related studies with conventional antidepressants [19].”
BackgroundMethodWang, X., Qin, J., Zhu, R., Zhang, S., Tian, S., Sun, Y., Wang, Q., Zhao, P., Tang, H., Wang, L., et al. (2021) · Brain Connectivity · doi:10.1089/brain.2021.0153 · Cited by 9
Predictors of fluoxetine remission for hospitalized patients with major depressive disorder
Lin, C., Lane, H., Chen, C., Juo, S. H., & Yen, C. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02235.x · Cited by 8
“Like baseline severity of depressive symptoms to predict remission, our finding is consistent with a couple of reports that have suggested that early improvement can be used as a predictor of antidepressant remission.(20,21,52) If variables (i.”
BackgroundResultIn Need of Psychiatric Help - Leave a Message after the Beep
Bridler, R., Orosz, A., Cattapan, K., & Stassen, H. H. (2012) · Psychopathology · doi:10.1159/000341729 · Cited by 9
Self-citationDavoodi, A., Holeňa, M., Brunovský, M., Kathpalia, A., Hlinka, J., Bareš, M., & Paluš, M. (2024) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.107362 · Cited by 10
Patient Response Trajectories in Major Depressive Disorder
Larsen, K. G., Kennedy, S. H., Reines, E. H., & Thase, M. E. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4370 · Cited by 7
Self-citationIs It Time to Try Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Again?
Perlis, R. H., & Fava, M. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4281 · Cited by 8
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
“Antidepressant response was also evident within one week in RCT meta-analyses [173,174] where there is statistical power to detect smaller differences, and by 2 weeks in clinical practice [25].”
BackgroundSontakke, S., Kadam, R., Tiple, P., Motghare, V. M., Bajait, C., & Kalikar, M. (2020) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_441_18 · Cited by 11
“, ≥20% improvement from baseline) in depressive symptoms in the first 2 weeks of treatment have a greater likelihood of stable treatment response and remission of symptoms.[17] In the vilazodone group, the highest number (70.”
BackgroundZuilhof, Z., Norris, S., Blondeau, C., Tessier, P., & Blier, P. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s175203 · Cited by 9
“Another problem with the treatment of MDD is that, although there exists a reliable predictor of nonresponse (ie, the lack of a 20% improvement after 2 weeks of treatment with a single drug), predictors of a positive response are yet lacking.(7,8) Nevertheless, specific medications can be selected in first intent to i…”
BackgroundAnhedonia in Major Depressive Disorder: Exploration of a Predictive Clinical Phenotype
Rizvi, S. J. (2015) · TSpace (University of Toronto) · Cited by 13
Zhang, Y.-R., Yang, T., Cui, X., Huang, C., Xie, G., Luo, X., & He, Y. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119511 · Cited by 8
Tian, S., Wang, Q., Zhang, S., Chen, Z., Dai, Z., Zhang, W., Yao, Z., & Lü, Q. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.096 · Cited by 7
Volkova, Т. V., Simonova, O. R., & Perlovich, G. L. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.123766 · Cited by 6
von Knorring, J., Baryshnikov, I., Jylhä, P. J., Talaslahti, T., Heikkinen, M. E., & Isometsä, E. T. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05390-8 · Cited by 8
“However, as early treatment response has been associated with better outcomes [16, 73], the possible predictive nature of this clinical factor should be noted in follow-up.”
BackgroundPredictive value of baseline resistance in early response to antidepressants
Icick, R., Millet, É., Curis, E., Bellivier, F., & Lépine, J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.03.002 · Cited by 7
“Two meta-analyses have fully supported these results, both including data from out and inpatient settings (Gorwood et al., 2013; Szegedi et al., 2009).”
ResultZheng, W., He, M., Gu, L.-M., Lao, G., Wang, D., Mai, J.-X., Wu, H., Nie, S., & Huang, X. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.027 · Cited by 7
Dimensions and Predictors of Personal Recovery in Major Depression
Luciano, M., Carmassi, C., & Albert, U. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_13 · Cited by 8
Peñaranda, A. P. B., Valencia, J. G., Guarín, M. R., Borrero, Á. E. A., Castro, S., Bradford, A. M. D. L. H., Riveros, P. M., Jaramillo, L. E., Brito, E., Acosta, C. A. P., et al. (2012) · Revista Colombiana de Psiquiatría · doi:10.1016/s0034-7450(14)60045-7 · Cited by 9
Electrophysiological predictors of early response to antidepressants in major depressive disorder
Tang, H., Xia, Y., Hua, L., Dai, Z., Wang, X., Yao, Z., & Lü, Q. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.118 · Cited by 4
Optimizing the Prediction of Depression Remission: A Longitudinal Machine Learning Approach
Carr, E., Rietschel, M., Mors, O. N., Henigsberg, N., Aitchison, K. J., Maier, W., Uher, R., FARMER, A. E., McGuffin, P., & Iniesta, R. (2024) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.33014 · Cited by 7
“By contrast, a large meta-analysis (Szegedi et al. 2009) found improvements within the first 2 weeks of treatment could predict treatment outcome with high sensitivity (> 80%).”
Vos, C. F., Birkenhäger, T. K., Nolen, W. A., van den Broek, W. W., ter Hark, S. E., Schellekens, A., Verkes, R., & Janzing, J. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001756 · Cited by 5
Fujino, Y., Tokuda, F., & Fujimoto, S. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1190464 · Cited by 10
“The proportion of patients with MDD who achieve symptomatic remission within 4 weeks of treatment with antidepressants has been shown to be 15–25%, with an increase up to 40% observed in the following few weeks (23).”
BackgroundPsychopharmacology Today: Where are We and Where Do We Go From Here?
Schwartz, T. L. (2010) · Mens Sana monographs · doi:10.4103/0973-1229.58816 · Cited by 6
“Some authors suggest that if there is no partial response within the fi rst two weeks then remission is doubtful (Szegedi et al. 2009).”
BackgroundIs the Ultimate Treatment Response Predictable with Early Response in Major Depressive Episode?
Ciftci, A., Ulaş, H., Topuzoǧlu, A., & Tunca, Z. (2015) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2015.10141 · Cited by 5
Early Improvement Predicts Treatment Outcomes for Patients With Acute Mania
Li, D., Lin, C., & Lu, M.-J. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000728 · Cited by 5
Park, C., Zuckerman, H., Subramaniapillai, M., Mansur, R. B., Rosenblat, J. D., Cao, B., Iacobucci, M., Lee, Y. L., Levitan, R. D., Blumberger, D. M., et al. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112767 · Cited by 5
Horikoshi, S., Kunii, Y., Matsumoto, J., Gotoh, D., Miura, I., & Yabe, H. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001176 · Cited by 6
“Relationships have been reported between early improvement and treatment outcome in major depressive disorders and schizophrenia patients.(9,10) Although antidementia drugs are widely used for patients with AD, such patients have been insufficiently evaluated for response to such treatment and administration has been…”
BackgroundOptimizing Antidepressant Management of Depression: Current Status and Future Perspectives
Schwartz, T. L., & Stahl, S. M. (2010) · Modern trends in psychiatry · doi:10.1159/000319517 · Cited by 6
Gilaberte, I., Romera, I., Pérez, V., Menchón, J. M., & Schacht, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.035 · Cited by 5
“…studies, were focused on the predictive value of early improvement for later response and remission (Baldwin et al., 2009; Nierenberg et al., 2000; Szegedi et al., 2003,2009; Lin et al., 2011; Henkel et al., 2009), evaluating several definitions of early improvement (Z20%, Z25%, Z30%, Z50%…”
BackgroundInfluentialWang, Y.-C., Lin, H.-T., Lu, M., Huang, M., Chen, C.-H., Wu, T., Wang, S. Z., Mao, W., Kuo, P., & Chen, H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00129 · Cited by 5
“An adequate duration was defined as at least 2 weeks (43, 44).”
BackgroundInoue, T., Fujimoto, S., Marumoto, T., Kitagawa, T., Ishida, K., Nakajima, T., Moriguchi, Y., Fujikawa, K., & Watanabe, K. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s340309 · Cited by 5
“These results could prove valuable to physicians when making treatment decisions.(4,9) Moderate sensitivity and comparatively low negative predictive values of early improvement may indicate that patients with MDD who do not demonstrate improvements in MADRS score 2 weeks after treatment initiation could potentially s…”
ResultGómez–Restrepo, C., Peñaranda, A. P. B., Valencia, J. G., Guarín, M. R., Narváez, E. B., Jaramillo, L. E., Acosta, C. A. P., Pedraza, R. S., & Castro, S. (2012) · Revista Colombiana de Psiquiatría · doi:10.1016/s0034-7450(14)60044-5 · Cited by 6
Qian, M., Shen, Z., Lin, M., Guan, T., Yang, J., Li, L., Shen, X., & Yuan, Y. (2016) · Asia-Pacific Psychiatry · doi:10.1111/appy.12270 · Cited by 4
“The sensitivity, specificity, positive predictive value, and negative predictive value were calculated as described by Szegedi et al. (2009).”
MethodDang, Y., Lu, B., Vanderwal, T., Castellanos, F. X., & Yan, C. (2024) · Psychological Medicine · doi:10.1017/s0033291724001156 · Cited by 3
Johansson, F., Flygare, O., Bäckman, J., Fondberg, R., Axelsson, E., Forsell, E., Cervin, M., Kaldo, V., Rück, C., & Wallert, J. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.092 · Cited by 3
Depression Treatment with Duloxetine and Reduction of Inability to Work
Happich, M., Schneider, E. M., Wilhelm, S., Zimmermann, T., & Schacht, A. (2012) · Depression Research and Treatment · doi:10.1155/2012/264854 · Cited by 4
Musil, R., Zhang, Y., Qu, S., Zhang, J., Sun, Y.-L., Liu, W.-L., Xie, L., Huang, Y., & Chen, J. (2016) · Deutsche Zeitschrift für Akupunktur · doi:10.1016/s0415-6412(16)30084-4 · Cited by 3
“Um diesen Wirkeintritt zu beschleunigen werden verschiedene Strategien eingesetzt, um ein frühes Ansprechen (Early Improvement) innerhalb von 14 Tagen zu erreichen, das für den weiteren Therapieverlauf einen hohen prädiktiven Vorhersagewert hat [2].”
Soerensen, K. T., Ishtiak‐Ahmed, K., Gasse, C., & Christensen, K. S. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2023.2173289 · Cited by 3
“In future studies, a time-lag period of 1–2weeks could be relevant as some studies have suggested a delayed onset of action for antidepressants of 1–2weeks [32,33].”
BackgroundHicks, P. B., Sevilimedu, V., Johnson, G. R., Tal, I., Chen, P., Davis, L. L., Vertrees, J. E., Zisook, S., & Mohamed, S. (2023) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20230017 · Cited by 3
Wang, T., Gao, C., Li, J., Li, L., Yue, Y., Liu, X., Chen, S., Hou, Z., Yin, Y., Jiang, W., et al. (2023) · The Canadian Journal of Psychiatry · doi:10.1177/07067437231210787 · Cited by 3
Prädiktive Faktoren der Depression und ihrer Therapie
Himmerich, H., Kohls, E., Hegerl, U., & Rummel‐Kluge, C. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4048-0 · Cited by 3
Kertzman, S., Vainder, M., Reznik, I., Gotzlav, Y., Weizman, A., Kotler, M., & Iancu, I. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283524d5c · Cited by 3
“It has been demonstrated that an early onset of improvement in symptoms (Szegedi et al., 2009; Farabaugh et al., 2010), fewer traumatic events, and well-integrated configurations of personality (Cloninger, 2004) have been associated with better response rates.”
BackgroundTokuoka, H., Nishihara, M., Fujikoshi, S., Yoshikawa, A., & Kuga, A. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s143093 · Cited by 3
“This treatment period in our study is quite early even compared with recent reports on early prediction using HAM-D scores at week 2.(5,6) At least one observational study supports the relationship between early improvement in PPS and remission.”
Methods to improve the efficiency of confirmatory clinical trials
Boessen, R. (2013) · Utrecht University Repository (Utrecht University) · Cited by 3
Han, K. Q., Ji, L., Xie, Q., Liu, L., Wu, X., He, L., Shi, Y., Zhang, R., He, G., Dong, Z., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.036 · Cited by 3
Sun, X., Wissow, L. S., & Liu, S. (2024) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462324004677 · Cited by 2
“We modeled the treatment effect to be a one-period boost in health (38), representedbyanincreasedprobability oftransitioning toahealthier state.”
Targum, S. D., Sanacora, G., Formella, A. E., Ceresoli‐Borroni, G., & Owen, R. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.006 · Cited by 2
Tauch, D., Winkel, S., & Quante, A. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.865756 · Cited by 3
Watanabe, T., Ueda, M., Ishiguro, S., Hayashi, Y., Aoki, A., Shinozaki, M., Kato, K., Akiyama, K., & Shimoda, K. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.382 · Cited by 2
Elbakary, N., Ouanes, S., Riaz, S., Abdallah, O., Mahran, I., Al‐Khuzaei, N., & Eltorki, Y. H. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03099-0 · Cited by 2
“ment (often defined by less than 20% reduction in a depression scale score) at two weeks may indicate that changes in depression management should be considered earlier than conventionally thought [16].”
BackgroundUnveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy
Shah, F. I., Shehzadi, S., Akram, F., Haq, I. U., Javed, B., Sabir, S., Kazim, Y., & Ashfaq, S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00994-7 · Cited by 4
Personal Recovery in People with Mental Disorders: The Achievement of a Meaningful Life
Pellegrini, L., & Albert, U. (2024) · Sustainable development goals series · doi:10.1007/978-3-031-70165-8_21 · Cited by 2
Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch-klinischer Bedeutung
Wehling, M., Burkhardt, H., Schwarz, S. T., Frölich, L., & Wedding, U. (2016) · Springer eBooks · doi:10.1007/978-3-662-48126-4_2 · Cited by 2
The Componential Approach Enhances the Effectiveness of 2-Week Trials for New Antidepressants
Katz, M. M., Berman, N., Bowden, C. L., & Frazer, A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182103461 · Cited by 2
How Can You Improve Quality Without Measuring Outcome? Getting From Here to There
Zimmerman, M. A., Young, D., Chelminski, I., & Dalrymple, K. L. (2010) · Cited by 3
Wang, J., Wang, F., Gu, M., Xiao, L., Xu, P., Guo, J., Jiang, S., Liu, Y., Liu, Y., Sun, W., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.748473 · Cited by 4
Schwarz, S. T., & Frölich, L. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0912-0_16 · Cited by 2
Grant Report on SCH: Personalized Depression Treatment Supported by Mobile Sensor Analytics
Kamath, J., Bi, J., Russell, A. C., & Wang, B. (2020) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20200010 · Cited by 2
Fu, Y., Ji, J. L., Shi, S. X., Zhang, H. Y., Lin, G. Z., Zhang, Y. L., Li, X., & Wu, W. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2175998 · Cited by 1
Stassen, H. H., Bachmann, S., Bridler, R., Cattapan, K., Hartmann, A. M., Rujescu, D., & Seifritz, E. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02062-4 · Cited by 1
Self-citationTamm, J., Takano, K., Just, L., Ehring, T. W., Rosenkranz, T., & Kopf‐Beck, J. (2025) · Behavior Therapy · doi:10.1016/j.beth.2025.08.002 · Cited by 1
Zhan, Y., Liu, H., & Wang, Y. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.036 · Cited by 5
“This finding aligns with research on early improvement as a predictor of eventual treatment success (Szegedi et al., 2009) and suggests that digital phenotyping may capture these early changes with greater sensitivity than clinical assessments.”
Zhang, J.-W., Yu, H., He, L., Zhang, R., Lv, H.-Z., Peng, Z.-W., & Wang, Y. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121634 · Cited by 1
Rkman, D., Nielsen, R. E., Licht, R. W., Martiny, K., Ritter, P. S., & Asztalos, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1765024 · Cited by 2
Furukawa, T. A., Noma, H., Kojima, M., Tajika, A., Toyomoto, R., Sakata, M., Luo, Y., Kosuke Inoue, Horikoshi, M., Akechi, T., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-113603 · Cited by 1
Lin, G., Chen, W., Chen, Y., Xu, L., Zhao, T., Wang, Z., Xu, M., Lu, C., Chen, M., Xia, S., et al. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02319-x · Cited by 1
“Depression was assessed using the 17-item Hamilton Depression Rating Scale (HAM-D 17 ) [26].”
Duan, N., Hu, J., Guan, J., Ji, Y., Huang, W., Qian, R. L., Zheng, H., Wan, Y., Wang, K., Xiao, G., et al. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08141-7 · Cited by 1
“It is noteworthy that in clinical decision-making, PPV and NPV may be more informative than sensitivity and specificity [38].”
Sanwald, S., Kammer, T., Connemann, B. J., Montag, C., & Kiefer, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-57641-9 · Cited by 1
Li, M., Wu, Z., Lu, X., Zalesky, A., Cheng, X., Zhang, Y., Cash, R. F. H., Jin, F., Jia, S., Xiao, Y., et al. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251084 · Cited by 3
Cooper‐Kazaz, R., Rigbi, A., & Lerer, B. (2010) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2010.04.007 · Cited by 1
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Stein, D. J., & Versiani, M. (2011) · Cited by 1
Katz, M. M., Berman, N., Bowden, C. L., & Frazer, A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000317 · Cited by 1
Ambulante psychiatrisch-psychotherapeutische Therapie
Böker, H., & Hartwich, P. (2015) · Springer eBooks · doi:10.1007/978-3-662-47765-6_31 · Cited by 1
Psychotherapy, Psychopharmacotherapy, and Neuromodulation
Hartwich, P., & Boeker, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-75112-2_26 · Cited by 2
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_67 · Cited by 3
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-53697-1_11 · Cited by 1
Tohen, M. F., Yu, J., Kramer, K., & Nguyen, H. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.100 · Cited by 1
Genetic determinants of antidepressant and antipsychotic drug response
Stassen, H. H., Bachmann, S., Bridler, R., Cattapan, K., Hartmann, A. M., Rujescu, D., Seifritz, E., Weisbrod, M., & Scharfetter, C. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01918-5 · Cited by 1
Self-citationPharmacological treatment of acute bipolar depression
Sachs, G. S., Sylvia, L. G., & Lund, H. G. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8567-5_9 · Cited by 1
Zhang, P. G. Y., Carroll, K., Hobart, M., Augustine, C., & Koch, G. G. (2017) · Pharmaceutical Statistics · doi:10.1002/pst.1839 · Cited by 1
“Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.([23,24]) Consequently, it was hypothesized that the presence of transient placebo responders (ie, an early placebo response at week 2 or 4 that diminished by the end…”
BackgroundUsing Patient-Centered Care to Improve Major Depressive Disorder Outcomes
Jackson (2021) · The Journal of Family Practice · doi:10.12788/jfp.0134 · Cited by 1
Hou, Z., Li, T., He, X., Zhang, Y., Chen, H., Jiang, W., Yin, Y., & Yuan, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.788398 · Cited by 1
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
From vulnerability to resilience against depression : the value of daily-life positive emotions
Geschwind, N. (2011) · Research Publications (Maastricht University) · doi:10.26481/dis.20111207ng · Cited by 3
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Leucht, S. (2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_244 · Cited by 1
Schwertfeger, N., Regen, F., Szegedi, A., & Benkert, O. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_76
Self-citation
Metadata
- Authors
- Szegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E.
- Affiliations
- University of Pennsylvania (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-02-24
- Volume
- 70
- Issue
- 3
- Pages
- 344-353
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2132699864
- Cited by
- 341
- References
- 0
- Citations by year
- 2026: 22 · 2025: 11 · 2024: 17 · 2023: 25 · 2022: 23 · 2021: 18 · 2020: 13 · 2019: 23 · 2018: 14 · 2017: 20 · 2016: 20 · 2015: 23 · 2014: 14 · 2013: 25 · 2012: 24
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- major depressive disorder, mirtazapine, early treatment response, treatment outcome prediction, antidepressant response, remission, rapid titration, dose titration, Hamilton Depression Rating Scale, predictive validity, negative predictive value, positive predictive value, sensitivity and specificity, antidepressant trials, inpatients and outpatients, treatment-resistant depression
- MeSH terms
- Mirtazapine, Antidepressive Agents, Clinical Trials as Topic, Major Depressive Disorder, Humans, Mianserin, Personality Inventory, Prognosis, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.